A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients with Advanced Cancers

The purpose of the study is to find the tolerable dose of an investigational drug CBLB502 that can be given to patients with cancer without causing severe side effects. Also, to find out the effectiveness of CBLB502 in advanced cancers.

Study Number: 

I 196111

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.